Cargando…
Probiotic as a Novel Treatment Strategy Against Liver Disease
CONTEXT: A symbiotic relationship between the liver and intestinal tract enables the healthy status of both organs. Microflora resident in intestinal lumen plays a significant role in hepatocytes function. Alterations to the type and amount of microorganisms that live in the intestinal tract can res...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631524/ https://www.ncbi.nlm.nih.gov/pubmed/23610585 http://dx.doi.org/10.5812/hepatmon.7521 |
_version_ | 1782266792428699648 |
---|---|
author | Imani Fooladi, Abbas Ali Mahmoodzadeh Hosseini, Hamideh Nourani, Mohammad Reza Khani, Soghra Alavian, Seyed Moayed |
author_facet | Imani Fooladi, Abbas Ali Mahmoodzadeh Hosseini, Hamideh Nourani, Mohammad Reza Khani, Soghra Alavian, Seyed Moayed |
author_sort | Imani Fooladi, Abbas Ali |
collection | PubMed |
description | CONTEXT: A symbiotic relationship between the liver and intestinal tract enables the healthy status of both organs. Microflora resident in intestinal lumen plays a significant role in hepatocytes function. Alterations to the type and amount of microorganisms that live in the intestinal tract can result in serious and harmful liver dysfunctions such as cirrhosis, nonalcoholic fatty liver disease, alcoholic liver disease, and hepatic encephalopathy. An increased number of pathogens, especially enterobacteriaceae, enterococci, and streptococci species causes the elevation of intestinal permeability and bacterial translocation. The presence of high levels of lipopolysaccharide (LPS) and bacterial substances in the blood result in a portal hypertension and ensuing hepatocytes damage. Several methods including the usage of antibiotics, prebiotics, and probiotics can be used to prevent the overgrowth of pathogens. Compared to prebiotic and antibiotic therapy, probiotics strains are a safer and less expensive therapy. Probiotics are "live microorganisms (according to the FAO/WHO) which when administered in adequate amounts confer a health benefit on the host”. EVIDENCE ACQUISITIONS: Data from numerous preclinical and clinical trials allows for control of the flora bacteria quantity, decreases in compounds derived from bacteria, and lowers proinflammatory production such as TNF-α, IL-6 and IFN-γ via down-regulation of the nuclear factor kappa B (NF-κ B). RESULTS: On the other hand, probiotic can reduce the urease activity of bacterial microflora. Furthermore, probiotic decreases fecal pH value and reduces ammonia adsorption. In addition, the serum level of liver enzymes and other substances synthesized by the liver are modulated subsequent to probiotic consumption. CONCLUSIONS: According to our knowledge, Probiotic therapy as a safe, inexpensive and a noninvasive strategy can reduce pathophysiological symptoms and improve different types of liver diseases without side effects. |
format | Online Article Text |
id | pubmed-3631524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-36315242013-04-22 Probiotic as a Novel Treatment Strategy Against Liver Disease Imani Fooladi, Abbas Ali Mahmoodzadeh Hosseini, Hamideh Nourani, Mohammad Reza Khani, Soghra Alavian, Seyed Moayed Hepat Mon Review Article CONTEXT: A symbiotic relationship between the liver and intestinal tract enables the healthy status of both organs. Microflora resident in intestinal lumen plays a significant role in hepatocytes function. Alterations to the type and amount of microorganisms that live in the intestinal tract can result in serious and harmful liver dysfunctions such as cirrhosis, nonalcoholic fatty liver disease, alcoholic liver disease, and hepatic encephalopathy. An increased number of pathogens, especially enterobacteriaceae, enterococci, and streptococci species causes the elevation of intestinal permeability and bacterial translocation. The presence of high levels of lipopolysaccharide (LPS) and bacterial substances in the blood result in a portal hypertension and ensuing hepatocytes damage. Several methods including the usage of antibiotics, prebiotics, and probiotics can be used to prevent the overgrowth of pathogens. Compared to prebiotic and antibiotic therapy, probiotics strains are a safer and less expensive therapy. Probiotics are "live microorganisms (according to the FAO/WHO) which when administered in adequate amounts confer a health benefit on the host”. EVIDENCE ACQUISITIONS: Data from numerous preclinical and clinical trials allows for control of the flora bacteria quantity, decreases in compounds derived from bacteria, and lowers proinflammatory production such as TNF-α, IL-6 and IFN-γ via down-regulation of the nuclear factor kappa B (NF-κ B). RESULTS: On the other hand, probiotic can reduce the urease activity of bacterial microflora. Furthermore, probiotic decreases fecal pH value and reduces ammonia adsorption. In addition, the serum level of liver enzymes and other substances synthesized by the liver are modulated subsequent to probiotic consumption. CONCLUSIONS: According to our knowledge, Probiotic therapy as a safe, inexpensive and a noninvasive strategy can reduce pathophysiological symptoms and improve different types of liver diseases without side effects. Kowsar 2013-02-25 /pmc/articles/PMC3631524/ /pubmed/23610585 http://dx.doi.org/10.5812/hepatmon.7521 Text en Copyright © 2013, Kowsar Corp. http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Imani Fooladi, Abbas Ali Mahmoodzadeh Hosseini, Hamideh Nourani, Mohammad Reza Khani, Soghra Alavian, Seyed Moayed Probiotic as a Novel Treatment Strategy Against Liver Disease |
title | Probiotic as a Novel Treatment Strategy Against Liver Disease |
title_full | Probiotic as a Novel Treatment Strategy Against Liver Disease |
title_fullStr | Probiotic as a Novel Treatment Strategy Against Liver Disease |
title_full_unstemmed | Probiotic as a Novel Treatment Strategy Against Liver Disease |
title_short | Probiotic as a Novel Treatment Strategy Against Liver Disease |
title_sort | probiotic as a novel treatment strategy against liver disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631524/ https://www.ncbi.nlm.nih.gov/pubmed/23610585 http://dx.doi.org/10.5812/hepatmon.7521 |
work_keys_str_mv | AT imanifooladiabbasali probioticasanoveltreatmentstrategyagainstliverdisease AT mahmoodzadehhosseinihamideh probioticasanoveltreatmentstrategyagainstliverdisease AT nouranimohammadreza probioticasanoveltreatmentstrategyagainstliverdisease AT khanisoghra probioticasanoveltreatmentstrategyagainstliverdisease AT alavianseyedmoayed probioticasanoveltreatmentstrategyagainstliverdisease |